ZoMaxx II Trial

Study of:
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of the ZoMaxxTM Drug Eluting Coronary Stent System as Compared to the TAXUSTM Express2TM Paclitaxel-Eluting Stent in de novo Coronary Arterial Lesions.

The purpose of this study is to compare ZoMaxxTM DES (ABT-578), a new drug eluting coronary stent, to the TAXUSTM Express 2 TM Paclitaxel-Eluting Coronary Stent, another marketed drug eluting stent currently in use.These kinds of drugs are used to prevent restenosis (re-blockage) of the artery. Patients will be evaluated by their doctor in the clinic at 1, 6, and 9 months and followed by telephone yearly for 5 years after the procedure. A subset of patients will have an angiogram at the 9 month visit.

• Timothy D. Henry, MD, FACC

• M. Nicholas Burke, MD
• Ivan J. Chavez, MD, FACC
• Daniel Lips, MD, FACC
• James D. Madison, MD, FACC
• Michael R. Mooney, MD, FACC
• Wesley R. Pedersen, MD, FACC
• Anil K. Poulose, MD, FACC
• Jay H. Traverse, MD, FACC, FAHA
• Yale Wang, MD, FACC, FSCAI

• Denise Windenburg, CCRC

For more information about this study or the Interventional Cardiology Research program at the Minneapolis Heart Institute Foundation, please contact Carol Stone at 612-863-9124.